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Large scale preparation of N-1-sulfonylcytosine derivatives has been optimized. The best me-
thod was the condensation reaction of silylated cytosine (1) with p-toluenesulfonyl chloride in
acetonitrile. Depending on the isolation procedure, 1-(p-toluenesulfonyl)cytosine 2 and 1-(p-
-toluenesulfonyl)cytosine hydrochloride 3 were isolated in 80 % and 75 % yields, respectively.
The NMR evidence presented shows that 2 appears as a common keto-amino tautomer in
DMSO-d6 solution while its hydrochloride 3 forms exclusively the rare keto-imino tautomer.
N-1-Sulfonylcytosine derivatives 2 and 3 were investigated for possible cytotoxic activity on
human normal fibroblasts (WI38), human pancreatic adenocarcinoma cells (MIAPaCa2), po-
orly differentiated cells from lymph node metastases of colon carcinoma (SW-620), and human
Burkitt lymphoma cells (Raji). MTT-cytotoxicity screens in human tissue culture cell lines
showed that both investigated compounds demonstrated antiproliferative activity in different
histological types of tumors. In comparison with 5-fluorouracil, some of N-1-sulfonylcytosine
derivatives showed 10 times stronger activity, with respect IC50. The inhibitory effect of the in-
vestigated derivatives on normal human cells was lower compared to their antitumor effects. In
addition to antitumor effects, hematological findings following the parenteral administration of
substances were also investigated.
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INTRODUCTION
From the aspect of biological activity, N-sulfonylpyrimi-
dine derivatives are very interesting compounds because
they have a combination of biologically active compo-
nents: a sulfonylcyclourea fragment and a nucleic acid
base. Sulfonylurea and its derivatives have been found
to have multifold biological and pharmacological interest.
Sulfonylureas are compounds with anticolesterolemic,1
antihypoglycemic,2 herbicidal3 and antitumor4 activity.
Diarylsulfonylureas and diphenylsulfonylureas display
very good antitumor features by inhibiting plasma mem-
brane NADH oxidase displayed on the surface of (lung,
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breast, colon, pancreas and kidney) tumor cells but not
on the surface of normal cells.4–8 On the other hand, these
compounds can be considered as modified nucleosides
with potential biological activity.
In the last few years, we have been involved in the
synthesis and biological evaluation of novel pyrimidine
derivatives possessing a sulfonamide pharmacophore as
potential antitumor agents (Figure 1). We have prepared
sulfonylcyclourea derivatives by attaching the sulfonyl
fragment onto N-1 of pyrimidine bases.9–11
The compounds showed potent growth inhibitory
activity against human tumor cell lines in vitro at con-
centrations of 10–5–10–8 M.12 In comparison with 5-FU,
some N-1-sulfonylpyrimidine derivatives showed 10 ti-
mes stronger inhibitory effects while the effects on nor-
mal human cell lines were much lower. Our additional
studies showed that N-1-sulfonylpyrimidine derivatives
have a strong antiproliferative activity and ability to in-
duce apoptosis in treated tumor cells.12
In the present work, we report on the large-scale syn-
thesis and spectroscopic studies of N-1-sulfonylcytosine
derivatives. The aim of the present study was to investi-
gate the in vitro antitumor activity of N-1-sulfonylcy-
tosine derivatives. In addition to the in vitro antitumor
activity, we also investigated the effects of parenteral ad-
ministration of sulfonylcyclourea derivatives (compared
to 5-FU) on the peripheral blood hematological findings.
5-FU was used for comparison with N-1-sulfonylcytosi-
ne derivatives because it is a standard chemotherapeutic
agent with pyrimidine structure.
EXPERIMENTAL
Chemistry General
Solvents were distilled from appropriate drying agents shortly
before use. TLC was carried out on DC-plastikfolien Kie-
selgel 60 F254. Melting points were determined on a Kofler
hot-stage apparatus and were uncorrected. UV Spectra
max/nm, log /dm3 mol–1 cm–1 were taken on a Philips
PU8700 UV/VIS spectrophotometer. IR spectra max/cm–1
were obtained for KBr pellets on a Perkin-Elmer 297 spec-
trophotometer. The 1H- and 13C-NMR spectra were record-
ed on a Varian Gemini 300 spectrometer, operating at 75.46
MHz for the 13C nucleus. The samples were dissolved in
DMSO-d6 and measured at 20 °C in 5 mm NMR tubes.
Sample concentrations were 0.1 mol dm–3 for 1H and 0.2
mol dm–3 for 13C measurements. Chemical shifts (/ppm)
were referred to TMS. Digital resolution was 0.3 Hz per
point in 1H- and 0.5 Hz per point in 13C-NMR one-dimen-
sional spectra. The applied techniques were standard 1H
and 13C with broadband proton decoupling; 13C gated de-
coupling, COSY, and HETCOR. For proton decoupling, the
Waltz-16 modulation was used. COSY spectra were recorded
in the magnitude mode with 1024 points in F2 dimension
and 256 increments in F1 dimension, zero-filled to 1024
points. Increments were measured with 16 scans, 4500 Hz
spectral width and a relaxation delay of 0.8 s. The corre-
sponding digital resolution was 8.9 Hz per point and 17.6
Hz per point in F2 and F1 dimensions, respectively. HET-
COR spectra were recorded with 2048 points in F2 dimen-
sion and 256 increments in F1 dimension, zero-filled to 512
points. Each increment was recorded by 96 scans with a re-
laxation delay of 1.0 s. Spectral widths were 19000 Hz in
F2 and 4500 Hz in F1 dimensions, and the corresponding
digital resolutions were 18.6 Hz per point and 17.6 Hz per
point, respectively. All mass spectrometric investigations
were performed using a Fourier transform mass spectrometer
ThermoQuest FT/MS 2001 DD (Madison, WI, USA) equ-
ipped with a 3 T superconducting magnet. Following the el-
ectron impact (EI) ion formation at 70 eV, a time delay of
100 s or 1 s was employed for relaxation of the initial cy-
clotron and axial motions by collision with background ne-
utrals. The samples were introduced by direct insertion.
1-(p-Toluenesulfonyl)cytosine 2
A mixture of cytosine (1) (7 g, 63 mmol) and N,O-bis(tri-
methylsilyl)acetamide (BSA) (46.62 mL, 189 mmol) was
heated under reflux in dry acetonitrile (140 mL) for 30 min-
utes. The solution was cooled to 0 °C and p-toluenesulfonyl
chloride (14.42 g, 75.6 mmol) was added. After heating un-
der reflux for 45 minutes, the solvent was evaporated. Me-
thanol was added to the residue and the resulting solid was
filtered off and recrystallized from hot methanol, yielding
white crystals of the product 2: 13.3 g (80 %); m.p. 216 °C;
(Ref. 10: m.p. 216 °C).
Additional data for 1-(p-toluenesulfonyl)cytosine 2:
The phenyl-protons (Ts) assignments were confirmed by
carbon-proton connectivity in the 1H/13C heteronuclear cor-
relation spectra (HETCOR). Additionally, in the NOESY
spectrum of 2, the assignment of Ts-c protons was proved
by their interaction with methyl-protons.
1H-NMR (DMSO-d6) /ppm: 8.14 (d, 1H, J6,5 = 7.8
Hz, H-6), 7.95 (brs, 2H, NH2), 7.87 (d, 2H, J = 8.1 Hz,
Ts-b), 7.46 (d, 2H, J = 8.1 Hz, Ts-c), 5.98 (d, 1H, J5,6 = 7.8
Hz, H-5), 2.42 (s, 3H, CH3); 13C-NMR (DMSO-d6) /ppm:
166.27 (s, C-4), 151.22 (s, C-2), 145.61 (s, Ts-d), 139.73 (d,
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Figure 1. From sulfonylurea derivatives to novel N-sulfonylpyrimi-
dine derivatives as a new type of sulfonylcycloureas.
C-6), 134.47 (s, Ts-a), 129.80 (d, Ts-c), 129.02 (d, Ts-b),
97.50 (d, C-5), 21.20 (q, CH3); MS (EI) exact mass calcd.
for C11H11N3O3S: m/e 265.051565 (M+), found 265.040053.
1-(p-Toluenesulfonyl)cytosine Hydrochloride 3
Method A: 1-(p-Toluenesulfonyl)cytosine 2 (3 g, 11.3 mmol)
was dissolved in hot methanol (ca 400 mL) and treated
with 3 % HCl/CH3OH (20 mL). After storage at 4 °C, the
main part of product 3 (1.91 g, 65 %) was crystallized from
solution and filtered off.
Method B: Amixture of cytosine (1) (7.75 g, 69.8 mmol)
and bis(trimethylsilyl)acetamide (BSA) (52 mL, 209 mmol)
was heated under reflux in dry acetonitrile (160 mL) for 30
minutes. The solution was cooled to 0 °C and p-toluenesul-
fonyl chloride (16 g, 84 mmol) was added. After heating
under reflux for 45 minutes, the solvent was evaporated.
The residue was treated with 3 % HCl/CH3OH (ca 100 mL)
and the resulting white crystals of 1-(p-toluenesulfonyl)cy-
tosine hydrochloride 3 were filtered off: 15.73 g (75 %);
m.p. 175–178 °C; UV (MeOH): max/nm 232,0 and 248,0,
log / dm3 mol–1 cm–1 3,97 and 4,00; IR (KBr) max/cm–1:
3350 (m), 3100 (s), 2700 (m, br), 2600 (vw), 1740 (s), 1668
(m), 1520 (m), 1485 (s), 1390 (w), 1375 (w), 1351 (w),
1300 (vw), 1255 (s), 1235 (vw), 1190 (w), 1184 (w), 1170
(s), 1136 (w), 1111 (w), 1080 (w), 1020 (w), 962 (vw), 865
(vw), 804 (w), 760 (w), 705 (w), 688 (m), 672 (m), 654
(m); 1H-NMR (DMSO-d6) /ppm: 10.40 (s, 1H, NH), 9.85
(brs, 1H, NH), 9.15 (s, 1H, NH), 8.30 (d, 1H, J6,5 = 7.8 Hz,
H-6), 7.89 (d, 2H, J = 8.3 Hz, Ts-b), 7.48 (d, 2H, J = 8.3
Hz, Ts-c), 6.28 (d, 1H, J5,6 = 7.8 Hz, H-5), 2.40 (s, 3H, CH3);
13C-NMR (DMSO-d6) /ppm: 160.91 (s, C-4), 146.93 (s,
C-2), 145.28 (s, Ts-d), 141.49 (d, C-6), 132.40 (s, Ts-a),
129.82 (d, Ts-c), 129.49 (d, Ts-b), 97.07 (d, C-5), 21.39 (q,
CH3); Anal. Calcd. for C11H12N3O3SCl (Mr = 301,76): C
43.78, H 4.01, N 13.93 %; found: C 43.81, H 3.93, N 13.85
%; MS (EI) exact mass calcd. for C11H12N3O3SCl: m/e
266,05939 (M-Cl+), found 266,066003.
In vitro Study:
1. Cell lines
Human pancreatic adenocarcinoma cells (MIAPaCa2), po-
orly differentiated cells from lymph node metastases of co-
lon carcinoma (SW-620), human Burkitt lymphoma cells
(Raji) and normal human fibroblasts (WI38) were obtained
from the Ru|er Bo{kovi} Institute, Division of Molecular
Medicine, Zagreb, Croatia.
2. Chemicals
RPMI-1640 medium and fetal bovine serum (FBS) were
obtained from Gibco BRL, Life Technologies (Paisley, UK),
Dulbecco’s Modified Eagle Medium (DMEM) with 10 %
heat inactivated FBS and tripsine-EDTA were purchased
from the Institute of Immunology Inc. (Zagreb, Croatia);
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT) and dimethylsulfoxyde (DMSO) were purchas-
ed from Merck (Darmstadt, Germany). Glutamine, penicil-
lin, streptomycin, and all others chemicals were obtained
from Sigma Chem. Co. (St. Louis, USA).
3. Cell Culture
Cells (MIAPaCa2, WI38, SW620) were grown as a mo-
nolayer in tissue culture flasks (250 mL) in DMEM supple-
mented with 10 % FBS, 2 mM glutamine, 100 U of penicil-
lin and 0.1 mg streptomycin in CO2 incubator (Shell Lab,
Sheldon Manufacturing, USA). Leukemia cells (Raji) were
grown in RPMI-1640 medium supplemented with 10 %
FBS. The cultures were equilibrated with humidified 5 %
CO2 in air at 37 °C. Trypan blue dye exclusion method was
used to assess cell viability.
4. Cell Proliferation Assay
Cell growth was quantified by the MTT assay.13 Cells (2 
104 cells per mL) were seeded onto 96-microwell plates
and allowed to attach overnight. After 24 hours, cells were
treated by addition of various concentration substances and
placed into a CO2 incubator for 72 hours. Controls were
grown under the same conditions without addition of the
test substances. After 72 hours of incubation, the medium
was removed and cells were washed 3 times with 100 L
Hank’s balanced salt solution (HBSS) before adding 40 L
of MTT (5 mg/mL). DMSO (160 L) was added to each
well to dissolve water-insoluble MTT-formazane crystals.
The plates were transferred to an Elisa plate reader (Stat fax
2100, Pharmacia Biotech, Uppsala, Sweden). Absorbance
was measured at 570 nm. Experiments were performed in
triplicates.
In vivo Study:
All experiments were performed on 13–15 week-old Wistar
rats weighting 200–250 g, bred at the Zagreb University
School of Medicine. Six animals were used in each group
per experiment. Food and water were supplied ad libitum.
Rats were divided into 7 groups. The first group was used
as a negative control, and physiological saline was adminis-
tered intraperitoneally. Groups 2 and 3 were treated with 7
mg/kg and 30 mg/kg of 1-(p-toluenesulfonyl)cytosine 2 (TsC),
and groups 4 and 5 with 7 mg/kg and 30 mg/kg of 1-(p-to-
luenesulfonyl)cytosine hydrochloride 3 (TsCHCl). Groups
6 and 7 were used as positive controls and were treated
with 7 mg/kg and 30 mg/kg of 5-FU, respectively.
Blood samples were taken on days 15 and 30 after the
treatment. The samples were collected and kept in tubes
containing ethylenediaminetetraacetic acid (EDTA) as anti-
coagulant. We analyzed peripheral blood values of red blood
cells (RBC), white blood cells (WBC), thrombocytes, packed
cell volume (PCV), hemoglobin concentration (Hb), mean
corpuscular volume (MCV), mean corpuscular hemoglobin
(MCH) and mean corpuscular hemoglobin concentration
(MCHC) using the Serono Baker System 9120 (Allentown,
Pennsylvania). Blood smears stained according to Roma-
novski were used to measure the differential WBC count.
The investigation protocol complied with the European Com-
munity guidelines for the use of experimental animals.
Statistical analysis and data plotting were performed
with the STATISTICATM software (version 5.0). Differen-
ces between the effects of different drug doses were tested
by means of ANOVA and Duncan’s test.
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RESULTS
Silylation of cytosine (1) was accomplished with N,O-
bis(trimethylsilyl)acetamide (BSA) in acetonitrile at 80
°C. Condensation of silylated cytosine with p-toluenesul-
fonyl chloride in acetonitrile gave 1-(p-toluenesulfonyl)-
cytosine 2 (TsC) in 80 % yield after recrystallization
from hot methanol (Scheme 1). If after heating under re-
flux for 45 minutes and evaporation of the solvent the
residue was treated with 3 % HCl/CH3OH, the resulting
white crystals of 1-(p-toluenesulfonyl)cytosine hydro-
chloride 3 (TsCHCl) were obtained in 75 % yield. Di-
rect treatment of a methanolic solution of TsC 2 with 3
% HCl/CH3OH also gave product TsCHCl 3 but in lo-
wer yield (65 %).
The in vitro cytotoxic effects of N-1-sulfonylcytosine
derivatives 2 and 3 on the growth of human fibroblasts
(WI38) and human tumor cells are summarized in Table
I. 5-Fluoruracil was used as the reference compound. As
shown in Table I, the investigated compounds inhibited
the growth of different tumor cell lines with varying
IC50 values (110–2 – 810–6 M). SW620 cells were the
most sensitive to substances 2 and 3. In comparison with
5-fluorouracil, N-1-sulfonylcytosine derivatives 2 and 3
showed 10 times stronger activity. Cytotoxicity of the
tested compounds 2 and 3 on human fibroblasts was re-
markably lower than their cytotoxicity on tumor cells.
Three-day parenteral administration of TsC, TsCHCl
and 5-FU did not cause statistically significant changes
in the peripheral blood thrombocytes, red blood cells
(RBC), packed cell volume (PCV), hemoglobin concen-
tration (Hb), mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH) and mean corpuscular
hemoglobin concentration (MCHC). Laboratory findings
were measured 15 and 30 days following the administra-
tion of substances. Significant deviations from the untre-
ated control values were detected in the treated groups
for the parameters of white blood cell count (WBC) and
differential WBC (Table II). WBC values were signifi-
cantly elevated on day 15 in the groups treated with 7
mg/kg and 30 mg/kg of TsCHCl (Table III, Figure 2a).
Segmented leukocytes were also significantly elevated
on day 15 in the group treated with 7 mg/kg of TsCHCl
(Table IV). On day 30, we observed significantly elevat-
ed values of the WBC count in groups treated with 7
mg/kg and 30 mg/kg of 5-FU (Table V, Figure 2b).
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TABLE I. Comparison of in vitro cytotoxic activity of 1-(p-toluene-
sulfonyl)cytosine (TsC), 1-(p-toluenesulfonyl)cytosine hydrochloride
(TsCHCl) and 5-FU on human normal fibroblasts (WI38) and dif-
ferent human tumor cell lines (SW620, MIAPaCa2, Raji)
IC50 / mol dm
–3
Compound WI38 SW620 MIAPaCa2 Raji
TsC 3  10–2 8  10–6 7  10–4 5  10–4
TsCHCl 1  10–2 5  10–5 5  10–4 8  10–4
5-FU 1  10–3 3  10–5 1  10–5 1  10–4
IC50 = Drug concentration that inhibited cell growth by 50 %.
Exponentially growing cells were treated with substances for 72 hours.
Cytotoxicity was analyzed with the MTT survival assay. Experiments
were performed at least 3 times.
TABLE II. ANOVA results of the white blood cell parameters in controls and different treatment groups
VARIABLE SS Effect MS Effect SS Error MS Error F p
WBC (15 days) 183.89* 30.65* 350.75* 10.96* 2.80* 0.026601*
SEGMENTED WBC (15 days) 2074.69* 345.78* 1797.70* 52.87* 6.54* 0.000117*
WBC (30 days) 263.57* 43.93* 123.81* 4.13* 10.64* 0.000002*
*p < 0.05
DISCUSSION
Only a few reports on 1-sulfonyluracil and 1-sufonyl-5-
-fluorouracil could be found in the literature. Martirosy-
an et al.14 isolated 1-(p-toluenesulfonyl)uracil as an un-
wanted product in the transformation of C-4 keto group
of uracil, and Kaldrikyn et al.15 examined the synthesis
of 1-p-alkoxybenzenesulfonyl-5-bromouracil derivatives
possessing antibacterial activity. According to Tada,16
benzoyl and arenylsulfonyl-5-fluorouracil derivatives
are more active and less toxic than 1-(2-tetrahydrofuryl)-
uracil in the Leukemia L/1210 system. However, the
synthesis and in vitro anticancer activity of 1-sulfonyl-
cytosine derivatives was described for the first time in
our patent.11
We have recently described the synthesis of several
novel N-1-sulfonyl, and N-1,NH-4-disulfonylpyrimidine
derivatives.9–11 Two methods were applied to the synthe-
sis of N-1-sulfonylpyrimidine derivatives: a) condensa-
tion of silylated pyrimidine bases with different sulfonyl
chlorides in acetonitrile, and b) reaction of pyrimidine
bases with sulfonyl chlorides in pyridine. In comparison,
N-1 sulfonylation of silylated cytosine 1 in acetonitrile
gave only one product, 1-(p-toluenesulfonyl)cytosine 2
in 80 % yield, while the reaction of 1 and p-toluenesul-
fonyl chloride in pyridine, besides the mono-sulfonylat-
ed product 2 (44 %), also gave the disulfonylated prod-
uct 4-N,1-di(p-toluenesulfonyl)cytosine in 24 % yield.10
Here we report a large scale synthesis of TsC 2 and
its hydrochloride TsCHCl 3. The best method was the
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TABLE III. Duncan’s multiple comparison test of the white blood cell count in controls and different treatment groups on day 15
GROUP 1M=9.0 2M=12.3 3M=11.7 4M=15.7 5M=15.1 6M=11.7 7M=11.1
1CONTROL
2TsC7
3TsC30
4TsCHCl7
5TsCHCl30
65-FU7
75-FU30
0.150955
0.221402
0.005292*
0.010539*
0.234349
0.322104
0.150955
0.763133
0.118160
0.180324
0.754248
0.565991
0.221402
0.763133
0.078768
0.130809
0.993515
0.754248
0.005292*
0.118160
0.078768
0.746746
0.073601
0.045986*
0.010539*
0.180324
0.130809
0.746746
0.120292
0.080232
0.234349
0.754248
0.993515
0.073601
0.120292
0.763133
0.322104
0.565991
0.754248
0.045986*
0.080232
0.763133
*p < 0.05; M = mean value ( 109/L)
TABLE IV. Duncan’s multiple comparison test of the segmented leukocyte count in controls and different treatment groups on day 15
GROUP 1M=13.3 2M=8.50 3M=10.8 4M=31.5 5M=14.6 6M=12.3 7M=13.0
1CONTROL
2TsC7
3TsC30
4TsCHCl7
5TsCHCl30
65-FU7
75-FU30
0.320607
0.598650
0.000266*
0.768019
0.827235
0.938148
0.320607
0.587376
0.000037*
0.217936
0.403243
0.343931
0.598650
0.587376
0.000093*
0.438563
0.726915
0.636146
0.000266*
0.000037*
0.000093*
0.000460*
0.000197*
0.000263*
0.768019
0.217936
0.438563
0.000460*
0.633205
0.726789
0.827235
0.403243
0.726915
0.000197*
0.633205
0.876602
0.938148
0.343931
0.636146
0.000263*
0.726789
0.876602
*p < 0.05; M = mean value ( 109/L)
TABLE V. Duncan’s multiple comparison test of the white blood cell count in controls and different treatment groups on day 30.
GROUP 1M=9.5 2M=9.9 3M=8.4 4M=10.5 5M=10.3 6M=14.3 7M=16.2
1CONTROL
2TsC7
3TsC30
4TsCHCl7
5TsCHCl30
65-FU7
75-FU30
0.745144
0.400370
0.472862
0.550123
0.001486*
0.000055*
0.745144
0.274153
0.660423
0.754998
0.002910*
0.000097*
0.400370
0.274153
0.149291
0.181703
0.000192*
0.000026*
0.472862
0.660423
0.149291
0.875971
0.005819*
0.000210*
0.550123
0.754998
0.181703
0.875971
0.005218*
0.000174*
0.001486*
0.002910*
0.000192*
0.005819*
0.005218*
0.151997
0.000055*
0.000097*
0.000026*
0.000210*
0.000174*
0.151997
*p < 0.05; M = mean value ( 109/L)
condensation reaction of silylated cytosine (1) with TsCl
in acetonitrile. Depending on the isolation procedure, 1-
-(p-toluenesulfonyl)cytosine 2 and 1-(p-toluenesulfonyl)-
cytosine hydrochloride 3 were isolated in 80 % and 75
% yields, respectively (Scheme 1).
1H-NMR spectra (all measured in DMSO-d6) of N-
-1-sulfonylated cytosine 2 differ from that of its hydro-
chloride 3, with respect to chemical shifts and multiplicity
(Figure 3). The most striking difference refers to N-pro-
tons. In the spectrum of 2, two amino protons at N-4,
readily exchangeable for deuterium by addition of D2O,
appear as a broadened singlet at  7.95 ppm.10
This is in accord with the existence of the keto-ami-
no tautomer, known to be the most stable form of unsub-
stituted cytosine. In the 1H-NMR spectrum of hydro-
chloride 3, two slightly broadened one-proton singlets
were observed at  10.40 and 9.15 ppm (exchangeable
with D2O). The large chemical shift difference between
these protons,  of 1.25 ppm, strongly suggests the for-
mation of the keto-imino tautomer. Inspection of the
COSY spectrum showed no cross-peaks between two
non-equivalent N-protons, completely ruling out the ge-
minal spin-spin interaction. Therefore, the observed sig-
nals for N-protons are not due to the chemically non-eq-
uivalent geminal N-protons but to protons at two different
N-atoms in 3.
Large scale preparation of N-1-sulfonylcytosine de-
rivatives 2 and 3 has been optimized. 1H-NMR spectrum
of hydrochloride 3 taken in DMSO-d6 revealed that in
contrast to 1-(p-toluensulfonyl)cytosine 2, which in the
same solvent forms the keto-amino tautomer, exclusive-
ly forms the keto-imino tautomer.
It is well known that 5-fluorouracil (5-FU) has anti-
tumor activity, but the therapeutic index of 5-FU is low.17
Consequently, there is much interest in finding molecu-
les that cause less cytotoxicity. Novel compounds, N-1-
sulfonylcytosine derivatives 2 and 3, demonstrated anti-
proliferative activity up to 10 times stronger compared
to 5-fluorouracil, with respect to IC50. At the same time,
we found them to be cell-specific because their cytotox-
ic effects on normal fibroblasts were weak. The given
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Figure 2. White blood cell count ( 109/L) in controls and different treatment groups on days 15 (a) and 30 (b).
Figure 3. 1H-NMR Spectra (DMSO-d6) of N-1-sulfonylcytosine de-
rivatives 2 (TsC) and 3 (TsCHCl).
a) b)
results show that both of the investigated substances rep-
resent a promising class of compounds that could be of
interest in cancer chemotherapy.
In vivo effects of TsC, TsCHCl, and 5-FU show
that on days 15 and 30, following 3 dose treatments with
either 7 mg/kg or 30 mg/kg, the substances caused no
significant influence on the peripheral blood thrombocy-
te, red blood cell and hemoglobin values. Significant de-
viations from the untreated control values were detected
for the peripheral white blood cell count of the animals
treated with 7 mg/kg and 30 mg/kg of TsCHCl (on day
15) and 5-FU (on day 30 of the trial). The data indicate
that different dynamic patterns of influence on the peri-
pheral white blood cells exist between TsCHCl and 5-
-FU. Tables III–V and Figure 2 show that TsCHCl could
be less toxic for the hematopoietic system than 5-FU,
e.g., due to faster recovery of white blood cells. Further
investigations are needed to evaluate suppressive effects
of the N-1-sulfonylcytosine derivatives on the blood white
cell proliferation and/or maturation.
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SA@ETAK
Sinteza, spektroskopska karakterizacija i biolo{ka aktivnost N-1-sulfonilcitozinskih derivata
Jelena Ka{nar-[amprec, Ljubica Glava{-Obrovac, Marina Pavlak, Ivica Mihaljevi}, Vladimir Mrljak,
Nikola [tambuk, Pa{ko Konjevoda i Biserka @ini}
Optimizirana je priprava ve}ih koli~ina N-1-sulfonilcitozinskih derivata, kondenzacijom sililiranoga cito-
zina i p-toluensulfonil klorida u acetonitrilu. Ovisno o na~inu izolacije dobiveni su 1-(p-toluensulfonil)citozin 2
(80 %) i 1-(p-toluensulfonil)citozin hidroklorid 3 (75 %). NMR eksperimenti pokazuju isklju~ivo nastajanje
keto-imino tautomera 3 u DMSO-d6 otopini, dok se 2 pojavljuje u uobi~ajenome keto-amino obliku. Ispitivani
su potencijalni citotoksi~ni u~inci N-1-sulfonilcitozinskih derivata 2 i 3 na fibroblastima ~ovjeka (WI38), sta-
nicama adenokarcinoma gu{tera~e (MIAPaCa2), slabo diferenciranim metastazama adenokarcinoma debelog
crijeva (SW-620) i stanicama Burkitt-ovog limfoma (Raji). Rezultati dobiveni MTT-testom pokazuju da ispi-
tivani spojevi djeluju antiproliferativno na razli~ite histolo{ke tipove tumora. U usporedbi s 5-fluorouracilom,
N-1-sulfonilcitozinski derivati pokazuju 10 puta ja~u inhibiciju rasta izlo`enih tumorskih stanica. Inhibicijski
u~inci ispitivanih spojeva na normalne stanice zna~ajno su slabiji u odnosu na protutumorske u~inke. Osim
antitumorskoga u~inka, ispitivani su i hematolo{ki parametri poslije parenteralne primjene ispitivanih tvari.
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